---
schema_version: "secwatch.filing_event.v1"
accession: "0001851734-22-000663"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:39:41.065884+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vistagen Q2 net loss $17.5M; PALISADE-2 restart after interim analysis

## Summary
- Net loss $17.5M vs $13.2M YoY; R&D spend $12.9M (+$2.9M) on PH94B/PH10 trials.
- Cash and equivalents $35.3M; shares outstanding 206.8M as of Nov 9, 2022.
- Independent interim analysis recommends continuing PALISADE-2 Phase 3 PH94B trial; restart preparations underway.
- Preliminary PALISADE Open Label data (n≈400) shows LSAS functional improvement; full assessment Q1 2023.
- IND submitted to FDA for PH10 Phase 1 study in healthy volunteers to enable Phase 2B in major depressive disorder.

## SEC filing metadata
- accession: 0001851734-22-000663
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/0001851734-22-000663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/vtgn20221110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001851734-22-000663
- JSON: https://secwatch.observer/filing/0001851734-22-000663.json
- Plain text: https://secwatch.observer/filing/0001851734-22-000663.txt

## Key facts
- Earnings Releases
  Vistagen Therapeutics, Inc. reported financial results for its fiscal year 2023 second quarter ended September 30, 2022.
  - Period: its fiscal year 2023 second quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 second quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000185173422000663/0001851734-22-000663-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.